title: Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine.
abstract: BACKGROUND
  Chronic treatment with selective serotonin reuptake inhibitors (SSRIs) can delay ejaculation in humans, but the extent of this effect differs between SSRIs. The involvement of 5-HT1A receptors is likely, since 5-HT1A receptor agonists accelerate ejaculation and chronic SSRI treatment is thought to desensitize 5-HT1A receptors.
  
  
  OBJECTIVE
  This study was conducted to examine the effects of chronic pretreatment with the SSRIs fluvoxamine and paroxetine on the facilitation of ejaculation induced by the 5-HT1A receptor agonist 8-OH-DPAT.
  
  
  METHODS
  Sexually experienced Wistar rats with normal ejaculatory behavior were treated for 22 days with vehicle, fluvoxamine (30 mg/kg/day), or paroxetine (10 or 20 mg/kg/day, p.o.). On day 22, rats received a challenge with saline or 8-OH-DPAT (0.4 mg/kg, s.c.). Sexual behavior was tested on days 1, 8, 15, and 22 of the SSRI-treatment.
  
  
  RESULTS
  Treatment with both doses of paroxetine, but not fluvoxamine, delayed ejaculation. 8-OH-DPAT strongly accelerated ejaculation under vehicle conditions. Pretreatment with paroxetine reduced the effects of 8-OH-DPAT on ejaculation in a dose-dependent manner and more strongly than fluvoxamine.
  
  
  CONCLUSIONS
  SSRIs affect 5-HT1A receptors involved in ejaculation. The degree to which this occurs, with paroxetine exerting a stronger effect than fluvoxamine, might determine the extent of SSRI-induced delayed ejaculation.
authors.affiliation: Department of Anatomy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. t.dejong@pnf.umcn.nl
authors.forename: Trynke R
authors.initials: TR
authors.lastname: de Jong
authors.forename: Tommy
authors.initials: T
authors.lastname: Pattij
authors.forename: Jan G
authors.initials: JG
authors.lastname: Veening
authors.forename: Marcel D
authors.initials: MD
authors.lastname: Waldinger
authors.forename: Alexander R
authors.initials: AR
authors.lastname: Cools
authors.forename: Berend
authors.initials: B
authors.lastname: Olivier
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology*; D000818:Animals; D004542:Ejaculation / Q000187:drug effects*; D005260:Female; D016666:Fluvoxamine / Q000494:pharmacology*; D008297:Male; D017374:Paroxetine / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D012726:Sexual Behavior, Animal / Q000187:drug effects
chemical_list: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D016666:Fluvoxamine; D017374:Paroxetine; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors
references.citation: Neuroreport. 1999 Feb 25;10(3):493-5
references.pmid: 10208577
references.citation: Eur J Pharmacol. 1999 Aug 20;379(1):1-6
references.pmid: 10499366
references.citation: Life Sci. 2003 Feb 28;72(15):1665-82
references.pmid: 12559389
references.citation: Pharmacol Biochem Behav. 1991 Jul;39(3):605-12
references.pmid: 1784589
references.citation: Eur J Pharmacol. 1992 Jan 14;210(2):121-9
references.pmid: 1534765
references.citation: Br J Pharmacol. 1998 Dec;125(8):1733-43
references.pmid: 9886765
references.citation: Brain Res. 1999 Mar 13;821(2):414-25
references.pmid: 10064829
references.citation: Neuropharmacology. 2000;39(1):110-22
references.pmid: 10665824
references.citation: Eur J Pharmacol. 2000 Sep 1;403(1-2):55-65
references.pmid: 10969144
references.citation: Neuropharmacology. 1995 May;34(5):501-8
references.pmid: 7566484
references.citation: Psychopharmacology (Berl). 1995 Feb;117(3):358-63
references.pmid: 7770611
references.citation: Physiol Behav. 2004 Nov 15;83(2):309-17
references.pmid: 15488547
references.citation: J Chem Neuroanat. 2001 Jan;21(1):63-73
references.pmid: 11173221
references.citation: Eur J Pharmacol. 1997 Jul 2;330(1):1-9
references.pmid: 9228408
references.citation: Psychopharmacology (Berl). 2002 Dec;164(4):392-400
references.pmid: 12457269
references.citation: Psychopharmacology (Berl). 2002 Mar;160(3):283-9
references.pmid: 11889497
references.citation: Alcohol. 1999 Apr;17(3):195-201
references.pmid: 10231167
references.citation: Psychopharmacology (Berl). 1999 Jun;144(4):355-62
references.pmid: 10435408
references.citation: Behav Brain Res. 1998 May;92(2):111-8
references.pmid: 9638953
references.citation: Pharmacol Ther. 2000 Jan;85(1):11-28
references.pmid: 10674711
references.citation: Neuropharmacology. 1999 Aug;38(8):1083-152
references.pmid: 10462127
references.citation: Eur Neuropsychopharmacol. 1999 Jul;9 Suppl 3:S81-6
references.pmid: 10523062
references.citation: Life Sci. 1989;45(14 ):1263-70
references.pmid: 2811596
references.citation: Neuroreport. 1998 Aug 3;9(11):2535-8
references.pmid: 9721928
references.citation: Psychopharmacology (Berl). 1997 Feb;129(3):197-205
references.pmid: 9084057
references.citation: Psychopharmacology (Berl). 1998 Jun;137(4):374-82
references.pmid: 9676898
references.citation: Brain Res. 1999 Feb 27;820(1-2):55-62
references.pmid: 10023030
references.citation: J Neural Transm Gen Sect. 1991;85(2):95-107
references.pmid: 1834089
references.citation: Pharmacol Biochem Behav. 1981 Nov;15(5):785-92
references.pmid: 6458826
references.citation: Physiol Behav. 1997 Oct;62(4):881-91
references.pmid: 9284512
references.citation: J Pharmacol Exp Ther. 1999 Jan;288(1):98-106
references.pmid: 9862759
references.citation: Psychopharmacology (Berl). 1999 Feb;142(1):95-101
references.pmid: 10102788
references.citation: J Clin Psychopharmacol. 1999 Feb;19(1):67-85
references.pmid: 9934946
references.citation: J Pharmacol Exp Ther. 1997 Sep;282(3):1581-90
references.pmid: 9316875
references.citation: Eur J Pharmacol. 1992 Mar 3;212(2-3):241-6
references.pmid: 1601066
references.citation: Neurochem Res. 1997 Aug;22(8):1065-70
references.pmid: 9239763
references.citation: BJU Int. 2004 Jan;93(2):201-7
references.pmid: 14690484
references.citation: Pharmacol Biochem Behav. 1992 Jul;42(3):529-33
references.pmid: 1409786
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1995 Aug;352(2):141-8
references.pmid: 7477436
references.citation: Eur Neuropsychopharmacol. 2001 Feb;11(1):15-24
references.pmid: 11226808
references.citation: J Biol Chem. 1993 Nov 5;268(31):23422-6
references.pmid: 8226867
references.citation: Int Clin Psychopharmacol. 1998 Jul;13 Suppl 6:S27-33
references.pmid: 9728672
references.citation: Int J Impot Res. 2004 Aug;16(4):369-81
references.pmid: 14961051